Literature DB >> 19012733

Transvenous intramyocardial cellular delivery increases retention in comparison to intracoronary delivery in a porcine model of acute myocardial infarction.

Jon C George1, Jonathan Goldberg, Matthew Joseph, Nasreen Abdulhameed, Joshua Crist, Hiranmoy Das, Vincent J Pompili.   

Abstract

BACKGROUND: Clinical trials using intracoronary (IC) delivery of cells have addressed efficacy but the optimal delivery technique is unknown. Our study aimed to determine whether transvenous intramyocardial (TVIM) approach was advantageous for cellular retention in AMI.
METHODS: Domestic pigs (n = 4) underwent catheterization with coronary angiography and ventriculography prior to infarction and pre- and post-cells. Pigs underwent 90-minute balloon occlusion of the left anterior descending artery (LAD). After one week they were prepared for IC (n = 2) or TVIM (n = 2) delivery of bone marrow mononuclear cells (MNC) labeled with GFP. IC infusion used an over-the-wire catheter to engage the LAD and balloon inflation to prevent retrograde flow. Venography via the coronary sinus was used for TVIM delivery. The anterior interventricular vein was engaged with a guidewire allowing use of the TransAccess catheter that is outfitted with an ultrasound tip for visualization. Animals were sacrificed one hour after delivery and tissue was analyzed.
RESULTS: Procedures were performed without complication and monitoring was uneventful. 1 x 10(8) MNC were isolated from each bone marrow (BM) preparation and 1 x 10(7) MNC delivered. Ventriculography at one week revealed wall motion abnormalities consistent with an anterior AMI. TVIM and IC delivery revealed mean 452 cells per section and 235 cells per section on average, respectively, in the infarct zone (P = 0.01).
CONCLUSION: We have demonstrated that TVIM approach for cell delivery is feasible and safe. Moreover, this approach may provide an advantage over IC infusion in retention of the cellular product; however, larger studies will be necessary.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19012733      PMCID: PMC4428662          DOI: 10.1111/j.1540-8183.2008.00390.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  24 in total

1.  Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials.

Authors:  Dongming Hou; Eyas Al-Shaykh Youssef; Todd J Brinton; Ping Zhang; Pamela Rogers; Erik T Price; Alan C Yeung; Brian H Johnstone; Paul G Yock; Keith L March
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

2.  Transcoronary stem cell delivery using physiological endothelium-targeting perfusion technique: the rationale and a pilot study involving a comparison with conventional over-the-wire balloon coronary occlusions in patients after recent myocardial infarction.

Authors:  Piotr Musiałek; Wiesława Tracz; Aleksander B Skotnicki; Krzysztof Zmudka; Piotr Pieniazek; Zbigniew Walter; Marta Szostek; Marcin Majka; Dorota Weglarska; Jarosław Zalewski; Maria Olszowska; Magdalena Kostkiewicz; Mieczysław Pasowicz; Piotr Klimeczek; Tadeusz Przewłocki
Journal:  Kardiol Pol       Date:  2006-05       Impact factor: 3.108

Review 3.  Enhancing myocardial plasmid expression by retrograde coronary venous delivery.

Authors:  Eyas Al-Shaykh Youssef; Ping Zhang; Pamela I Rogers; Patrice Tremble; Joe Rokovich; Brian H Johnstone; Keith L March; Dongming Hou
Journal:  Catheter Cardiovasc Interv       Date:  2005-08       Impact factor: 2.692

4.  Transplantation of mesenchymal stem cells from human bone marrow improves damaged heart function in rats.

Authors:  Mai Hou; Ke-ming Yang; Hao Zhang; Wei-Quan Zhu; Fu-jian Duan; Hao Wang; Yun-hu Song; Ying-jie Wei; Sheng-shou Hu
Journal:  Int J Cardiol       Date:  2006-08-04       Impact factor: 4.164

5.  Transplanted human umbilical cord blood mononuclear cells improve left ventricular function through angiogenesis in myocardial infarction.

Authors:  Cheng-heng Hu; Gui-fu Wu; Xiao-qing Wang; Yan-hua Yang; Zhi-min Du; Xiao-hong He; Peng Xiang
Journal:  Chin Med J (Engl)       Date:  2006-09-20       Impact factor: 2.628

6.  Percutaneous trans-coronary-venous transplantation of autologous skeletal myoblasts in the treatment of post-infarction myocardial contractility impairment: the POZNAN trial.

Authors:  Tomasz Siminiak; Dorota Fiszer; Olga Jerzykowska; Beata Grygielska; Natalia Rozwadowska; Piotr Kałmucki; Maciej Kurpisz
Journal:  Eur Heart J       Date:  2005-03-10       Impact factor: 29.983

7.  Mobilized bone marrow cells repair the infarcted heart, improving function and survival.

Authors:  D Orlic; J Kajstura; S Chimenti; F Limana; I Jakoniuk; F Quaini; B Nadal-Ginard; D M Bodine; A Leri; P Anversa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

8.  The safety of autologous intracoronary stem cell injections in a porcine model of chronic myocardial ischemia.

Authors:  Shyam Bhakta; Nicholas J Greco; Marcie R Finney; Paul E Scheid; Robert D Hoffman; Matthew E Joseph; Jason J Banks; Mary J Laughlin; Vincent J Pompili
Journal:  J Invasive Cardiol       Date:  2006-05       Impact factor: 2.022

9.  Intramyocardial microdepot injection increases the efficacy of skeletal myoblast transplantation.

Authors:  Harald C Ott; Ruth Kroess; Nikolaos Bonaros; Rainer Marksteiner; Eva Margreiter; Thomas Schachner; Guenther Laufer; Steffen Hering
Journal:  Eur J Cardiothorac Surg       Date:  2005-04-07       Impact factor: 4.191

10.  Widespread regional myocardial transfection by plasmid encoding Del-1 following retrograde coronary venous delivery.

Authors:  Dongming Hou; Fiona Maclaughlin; Mary Thiesse; Vipul R Panchal; Bas C A M Bekkers; Elizabeth A Wilson; Pamela I Rogers; Michael C Coleman; Keith L March
Journal:  Catheter Cardiovasc Interv       Date:  2003-02       Impact factor: 2.692

View more
  11 in total

Review 1.  Cell delivery routes for stem cell therapy to the heart: current and future approaches.

Authors:  Niall G Campbell; Ken Suzuki
Journal:  J Cardiovasc Transl Res       Date:  2012-05-31       Impact factor: 4.132

Review 2.  Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.

Authors:  Santosh K Sanganalmath; Roberto Bolli
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

Review 3.  Human coronary venous anatomy: implications for interventions.

Authors:  Julianne H Spencer; Sara E Anderson; Paul A Iaizzo
Journal:  J Cardiovasc Transl Res       Date:  2013-01-11       Impact factor: 4.132

Review 4.  Intracoronary delivery of bone-marrow-derived stem cells.

Authors:  Quang T Bui; Zachary M Gertz; Robert L Wilensky
Journal:  Stem Cell Res Ther       Date:  2010-09-23       Impact factor: 6.832

Review 5.  Non-surgical stem cell delivery strategies and in vivo cell tracking to injured myocardium.

Authors:  Tycho I G van der Spoel; Joe Chun-Tsu Lee; Krijn Vrijsen; Joost P G Sluijter; Maarten Jan M Cramer; Pieter A Doevendans; Eric van Belle; Steven A J Chamuleau
Journal:  Int J Cardiovasc Imaging       Date:  2010-06-25       Impact factor: 2.357

6.  Safety and feasibility of percutaneous retrograde coronary sinus delivery of autologous bone marrow mononuclear cell transplantation in patients with chronic refractory angina.

Authors:  Jorge Tuma; Roberto Fernández-Viña; Antonio Carrasco; Jorge Castillo; Carlos Cruz; Alvaro Carrillo; Jose Ercilla; Carlos Yarleque; Jaime Cunza; Timothy D Henry; Amit N Patel
Journal:  J Transl Med       Date:  2011-10-26       Impact factor: 5.531

7.  Extracellular high mobility group box 1 plays a role in the effect of bone marrow mononuclear cell transplantation for heart failure.

Authors:  Masahiro Kaneko; Yasunori Shintani; Takuya Narita; Chiho Ikebe; Nobuko Tano; Kenichi Yamahara; Satsuki Fukushima; Steven R Coppen; Ken Suzuki
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

8.  Allogeneic cardiospheres delivered via percutaneous transendocardial injection increase viable myocardium, decrease scar size, and attenuate cardiac dilatation in porcine ischemic cardiomyopathy.

Authors:  Kristine Yee; Konstantinos Malliaras; Hideaki Kanazawa; Eleni Tseliou; Ke Cheng; Daniel J Luthringer; Chak-Sum Ho; Kentaro Takayama; Naoto Minamino; James F Dawkins; Supurna Chowdhury; Doan Trang Duong; Jeffrey Seinfeld; Ryan C Middleton; Rohan Dharmakumar; Debiao Li; Linda Marbán; Raj R Makkar; Eduardo Marbán
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

Review 9.  Endometrial regenerative cells for treatment of heart failure: a new stem cell enters the clinic.

Authors:  Leo Bockeria; Vladimir Bogin; Olga Bockeria; Tatyana Le; Bagrat Alekyan; Erik J Woods; Amalia A Brown; Thomas E Ichim; Amit N Patel
Journal:  J Transl Med       Date:  2013-03-05       Impact factor: 5.531

Review 10.  Hematopoietic stem cells: ex-vivo expansion and therapeutic potential for myocardial ischemia.

Authors:  Jingwei Lu; Vincent J Pompili; Hiranmoy Das
Journal:  Stem Cells Cloning       Date:  2010-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.